Management
Treatment & management
No treatment cures Ménière’s, and its fluctuating natural history flatters every intervention. Management is a ladder: control attacks with the least invasive measure that works, and protect the hearing.
What the evidence really supports
Most people are managed with diet and lifestyle changes and reassurance, with stronger treatments added only if attacks stay frequent or severe. Because the disease comes and goes on its own, it can be hard to tell what is really working.
The evidence is humbling. The randomised BEMED trial found betahistine no better than placebo for attack frequency, yet it remains widely used and well tolerated.1 For escalation, intratympanic methylprednisolone was non-inferior to gentamicin in a head-to-head trial — a hearing-sparing first injectable.2
Intratympanic gentamicin reliably controls vertigo by chemical ablation, at the cost of hearing in a proportion of patients — reserve it, and titrate.3 Frame all of this against the natural history and the 2020 guideline’s emphasis on shared decision-making and counselling.4
The treatment ladder
Three steps: conservative measures for everyone, intratympanic therapy when control is inadequate, and surgery reserved for intractable disease. Escalate only as far as needed.
Conservative — first-line
- Diet & lifestyleLow-salt diet; moderate caffeine, alcohol and nicotine; regular sleep and stress management.
- Reassurance & a written planExplain the natural history; most attacks settle and hearing stabilises over years.
- Acute attack reliefShort-course antiemetics / vestibular suppressants for a severe attack only — not daily.
- Betahistine / diuretics; VRTCommonly used though evidence is modest (BEMED: betahistine ≈ placebo). VRT for interictal imbalance.
Intratympanic — escalation
- Intratympanic steroidsGland- and hearing-sparing; non-inferior to gentamicin in a head-to-head trial. A reasonable first injectable.
- Intratympanic gentamicinChemically ablates vestibular function in the affected ear — effective for vertigo, at the risk of further hearing loss.
Surgical — intractable disease
- Endolymphatic sac surgeryDecompression/shunt; non-destructive and hearing-preserving, though its efficacy is debated.
- Vestibular neurectomySections the vestibular nerve; abolishes vertigo while preserving hearing — needs craniotomy.
- LabyrinthectomyDefinitive ablation for intractable vertigo in an ear with no useful hearing.
Escalate only as far as needed — most patients are controlled on step 1. Ablative options trade vestibular function (and sometimes hearing) for vertigo control, so weigh the hearing in the affected ear before choosing. Avoid chronic vestibular suppressants, which blunt central compensation.
Choosing an escalation
The pivotal question is the hearing in the affected ear. With useful hearing, prefer hearing-sparing options — intratympanic steroids, endolymphatic sac surgery, or vestibular neurectomy. With non-serviceable hearing and intractable vertigo, ablative options — intratympanic gentamicin or labyrinthectomy — trade the vestibular function you have already lost for reliable vertigo control.3 Either way, vestibular rehabilitation helps the brain compensate afterwards.
Counselling and the long view
Explain the relapsing-remitting course, that attacks tend to burn out over years as the hearing stabilises at a lower level, and that the goal is to control vertigo and preserve function rather than cure. Manage comorbid anxiety and, where the picture overlaps, treat a coexisting vestibular migraine in parallel.
Key points
- Conservative diet/lifestyle measures first; escalate only for frequent or disabling attacks.
- Betahistine is no better than placebo in trials (BEMED) but remains commonly used.
- Intratympanic steroids (hearing-sparing) are non-inferior to gentamicin; gentamicin is ablative.
- Let the hearing in the affected ear guide hearing-sparing vs ablative escalation.